Clinical trials: Chronic Heart Failure With Reduced Ejection Fraction
- Condition Chronic Heart Failure With Reduced Ejection Fraction
- Funder type Industry (pharma, biotech, devices)
Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction
A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)
This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with heart failure with reduced ejection fraction (HFrEF).
- Trial name
- VICTORIA (NCT02861534)
- Testing
- Vericiguat
- Volunteers
- 5,050 people
- Sponsor
- Merck Sharp & Dohme LLC
Heart Failure
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)
Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard therapy for heart failure with reduced…
- Trial name
- NCT01951625
- Testing
- Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg)
- Where
- 157 sites in United States, Australia and 22 more
- Volunteers
- 456 people
- Sponsor
- Bayer
Heart Failure, Reduced Ejection Fraction
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
The purpose of this study was to investigate the effects of initiation of sacubitril/valsartan vs enalapril treatment on objective measures of both waking activity and sleep in subjects with heart failure with reduced ejection…
- Trial name
- AWAKE-HF (NCT02970669)
- Testing
- sacubitril/valsartan (LCZ696), enalapril
- Where
- 23 sites in United States
- Volunteers
- 140 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
ALLEVIATE-HFrEF Study
Patients with heart failure and reduced left ventricular ejection fraction (HFrEF, EF ≤ 40%) with mild to moderate functional limitation will be evaluated for treatment via creation of a no-implant interatrial shunt using…
- Trial name
- NCT05133089
- Testing
- ALV1 System
- Where
- Georgia
- Volunteers
- 5 people
- Sponsor
- Alleviant Medical, Inc.
Chronic Heart Failure With Reduced Ejection Fraction
A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction
Researchers are looking for a better way to treat people who have chronic heart failure with reduced ejection fraction. Chronic heart failure with reduced ejection fraction (HFrEF) is a long-term condition that occurs when the…
- Trial name
- NCT06195930
- Testing
- Vericiguat (BAY1021189) 5 mg
- Where
- 35 sites in United States, Argentina and 5 more
- Volunteers
- 106 people
- Sponsor
- Bayer
Chronic Heart Failure With Reduced Ejection Fraction
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
The purpose of this study was to collect safety and tolerability data on LCZ696 in eligible PARADIGM-HF patients who received open-label investigational drug.
- Trial name
- NCT02226120
- Testing
- LCZ696
- Where
- 394 sites in United States, Argentina and 39 more
- Volunteers
- 1,980 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Study of JK07 in Patients With Chronic Heart Failure
This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure.
- Trial name
- RENEU-HF (NCT06369298)
- Testing
- JK07
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 282 people
- Sponsor
- Salubris Biotherapeutics Inc
Heart Failure With Reduced Ejection Fraction (HFrEF)
A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure
The primary purpose of the study is to evaluate the safety and efficacy of 2 doses of AC01 compared to placebo over 12 weeks in participants with chronic advanced HFrEF.
- Trial name
- GOAL-HF2 (NCT07584967)
- Testing
- AC01
- Volunteers
- 400 people
- Sponsor
- AnaCardio AB
Chronic Heart Failure
Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-861 administered once daily for 12 weeks in subjects with heart failure with reduced ejection fraction (HFrEF) who are on a stable…
- Trial name
- POWER-HF (NCT06017609)
- Testing
- JTT-861 Capsules
- Where
- 75 sites in United States, Bulgaria and 4 more
- Volunteers
- 314 people
- Sponsor
- Shionogi Inc.
Chronic Heart Failure With Reduced Ejection Fraction
A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction
The main purpose of this study is to determine the tolerability and safety of LY3461767 with any side effects that might be associated with it.
- Trial name
- NCT04840914
- Testing
- LY3461767
- Where
- 7 sites in United States, Japan
- Volunteers
- 44 people
- Sponsor
- Eli Lilly and Company
Heart Failure
NoYA RAISE Trial II (Radiofrequency Ablation-Based Interatrial Shunt for Heart Failure)
A Prospective, Multiple Center, and Objective Performance Criteria Study to Evaluate the NoYA™ Radiofrequency Interatrial Shunt System manufactured by NoYA Medtech (Hangzhou) Co., Ltd.
- Trial name
- NCT05375110
- Testing
- NoYA™ Radiofrequency Interatrial Shunt System
- Where
- 31 sites in China
- Volunteers
- 120 people
- Sponsor
- Hangzhou NOYA MedTech Co. Ltm.
Heart Failure, Heart Failure With Reduced Ejection Fraction
Effectiveness of CRD-740 in Heart Failure
This is a study evaluating the effectiveness of CRD-740 in patients with either Heart Failure with Reduced Ejection Fraction (HFrEF) or Heart Failure with Preserved Ejection Fraction (HFpEF) after 12 weeks of treatment.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Cardiovascular Diseases
- Trial name
- CARDINAL-HF (NCT05409183)
- Testing
- CRD-740
- Where
- 34 sites in United States, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Heart Failure
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%.
- Trial name
- NCT06935370
- Testing
- vicadrostat, empagliflozin
- Where
- 594 sites in United States, Argentina and 27 more
- Volunteers
- 4,200 people
- Sponsor
- Boehringer Ingelheim
Chronic Heart Failure With Reduced Ejection Fraction
The VERIFY Study: An Observational Study Called VERIFY to Learn More About the Use of Vericiguat in People With Chronic Heart Failure With Reduced Ejection Fraction
This is an observational study in which the health data of people with chronic heart failure with reduced ejection fraction (HFrEF) are collected using administrative claims data.
- Trial name
- NCT05974189
- Where
- Germany
- Volunteers
- 1,391 people
- Sponsor
- Bayer
Heart Failure
Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction
The purpose of this study is to determine if treatment with omecamtiv mecarbil when added to standard of care is well tolerated and superior to placebo in reducing the risk of cardiovascular death or heart failure events in…
- Trial name
- GALACTIC-HF (NCT02929329)
- Testing
- Omecamtiv Mecarbil, Standard of Care
- Where
- 1,033 sites in United States, Argentina and 34 more
- Volunteers
- 8,256 people
- Sponsor
- Cytokinetics
Chronic Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction
An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan
This is an observational study in which data already collected from people with chronic heart failure is studied. Chronic HFrEF is a long-term condition where the left side of the heart does not pump blood out to the body as well…
- Trial name
- ROVER Japan (NCT06697353)
- Testing
- vericiguat (BAY 1021189)
- Where
- Japan
- Volunteers
- 4,936 people
- Sponsor
- Bayer
Chronic Heart Failure, Left Ventricular (LV) Systolic Dysfunction
A Study Evaluating an Implantable Cardiac Microcurrent Device in Patients With Chronic Heart Failure
This study evaluates the safety and performance/effectiveness of the C-MIC System, an active implantable medical device designed to treat patients with heart failure with reduced ejection fraction (HFrEF).
- Conditions
- Chronic Heart Failure, Left Ventricular (LV) Systolic Dysfunction, Ischemic and Non-ischemic Cardiomyopathy
- Trial name
- NCT07795359
- Testing
- Subcutaneous cardiac microcurrent treatment
- Volunteers
- 60 people
- Sponsor
- Berlin Heals GmbH
Heart Failure
A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction
The purpose of this study is test the safety and tolerability of BMS-986224 and its effects on the body in healthy subjects and subjects with chronic heart failure with reduced ejection fraction
- Trial name
- NCT03281122
- Testing
- BMS-986224
- Where
- 18 sites in Czechia, Netherlands and 3 more
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Chronic Heart Failure With Reduced Ejection Fraction
Omecamtiv Mecarbil Post-trial Access Study
The primary objective of this study is to provide access to omecamtiv mecarbil for participants who have completed GALACTIC-HF 20110203.
- Trial name
- NCT04464525
- Testing
- Omecamtiv mecarbil
- Sponsor
- Cytokinetics
Chronic Heart Failure With Reduced Ejection Fraction
An Observational Study Called ROVER to Learn More About How Well Vericiguat Works in People Who Were Newly Treated With Vericiguat in Routine Medical Care in Germany
This is an observational study in which data already collected from people treated with vericiguat are studied. In observational studies, only observations are made without participants receiving any advice or any changes to…
- Trial name
- ROVER (NCT06486844)
- Testing
- Vericiguat (Verquvo, BAY1021189)
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Bayer